In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans

Documenti analoghi

• In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole
  di: Pfaller, M. A., et al.
  Pubblicazione: (1998)
• In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America
  di: Diekema, D. J., et al.
  Pubblicazione: (1999)
• In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans
  di: Pfaller, M. A., et al.
  Pubblicazione: (2001)
• Characterization of Heteroresistance to Fluconazole among Clinical Isolates of Cryptococcus neoformans
  di: Yamazumi, T., et al.
  Pubblicazione: (2003)
• In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp.
  di: Pfaller, M. A., et al.
  Pubblicazione: (2002)